Sun Pharma Advanced Research Company Ltd approves Q2 FY27 results, reporting consolidated revenue of ₹30.03 cr and net loss of ₹24.39 cr
- Revenue rose 282.1% year on year but fell 24.8% sequentially.
- Net loss narrowed from ₹75.85 cr a year earlier; the prior-quarter loss was ₹20.78 cr.
- No exceptional item was reported; results were accompanied by the statutory auditors’ limited review report.